PT  - JOURNAL ARTICLE
AU  - Tawnie J Braaten
AU  - Julie R Brahmer
AU  - Patrick M Forde
AU  - Dung Le
AU  - Evan J Lipson
AU  - Jarushka Naidoo
AU  - Megan Schollenberger
AU  - Lei Zheng
AU  - Clifton O Bingham 3rd
AU  - Ami A Shah
AU  - Laura C Cappelli
TI  - Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation
AID  - 10.1136/annrheumdis-2019-216109
DP  - 2020 Mar 01
TA  - Annals of the Rheumatic Diseases
PG  - 332--338
VI  - 79
IP  - 3
4099  - http://ard.bmj.com/content/79/3/332.short
4100  - http://ard.bmj.com/content/79/3/332.full
SO  - Ann Rheum Dis2020 Mar 01; 79
AB  - Objective We sought to investigate the long-term outcomes of patients who develop immune checkpoint inhibitor (ICI)-induced inflammatory arthritis (IA), to define factors associated with IA persistence after ICI cessation, the need for immunosuppressants and the impact of these medications on underlying malignancies.Methods We conducted a prospective observational study of patients referred for IA associated with ICIs. Patients were recruited from June 2015 to December 2018. Information was obtained at the baseline visit, and follow-up visits occurred at varying intervals for up to 24 months from ICI cessation. Kaplan-Meier curves were developed to characterise IA persistence. Cox proportional hazards models were used to assess the influence of various factors on IA persistence. Logistic regression was used to evaluate the impact of IA treatment on tumour response.Results Sixty patients were monitored with a median follow-up after ICI cessation of 9 months. A majority (53.3%) had active IA at their most recent follow-up. IA was less likely to improve in those with longer duration of ICI use, in those receiving combination ICI therapy, and in patients with multiple other immune-related adverse events. Tumour response did not appear to be impacted by immunosuppression. Although not statistically significant, persistent IA was correlated with a better tumour response (complete or partial response).Conclusion ICI-induced IA can become a long-term disease necessitating management by rheumatology for immunomodulatory treatment. Importantly, the use of immunomodulatory treatment has not been shown to impact cancer outcomes in this study.